[Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease].
Mesalazine (5-aminosalicylic acid) and sulfasalazine are widely used in the treatment of inflammatory bowel disease. The pulmonary toxicity related to sulfasalazine was well-recognized complication and it was caused by sulfapyridine moiety in sulfasalazine. However, the lung injury related to mesalazine has rarely been reported. A thirty five-year-old man with Crohn's disease who was treated with mesalazine complained fever and dry cough. The finding of bilateral wandering pulmonary infiltration, peripheral eosinophilia and increased eosinophils in bronchoalveolar lavage were consistent with eosinophilic pneumonia. His symptoms and laboratory findings were markedly improved after the discontinuation of mesalazine. The mesalazine-induced eosinophilic pneumonia was diagnosed according to his clinical course. This report shows that the eosinophilic pneumonia should be considered in patients who develop pulmonary involvement with inflammatory bowel disease receiving mesalazine therapy.
Park
Jeung Eun
JE
Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea.
Hwangbo
Young
Y
Chang
Rin
R
Chang
Young Woon
YW
Jang
Jae-Young
JY
Kim
Byung-Ho
BH
Dong
Seok-Ho
SH
Kim
Hyo-Jong
HJ
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use; D011657:Pulmonary Eosinophilia / Q000139:chemically induced / Q000175:diagnosis* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine